Diagnostic Study for Lung Cancer Detection Test

Lung Cancer Clinical Trial

Official title:

Clinical Study of BioView Target -FISH Lung Cancer Detection Test

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01700452
• Other study ID #: LCD Test 17Jul2012
• Secondary ID: Revision 3
• Status: Completed
• Phase: N/A
• First received: September 10, 2012
• Last updated: July 18, 2016
• Start date: April 2012
• Est. completion date: April 2016

Study information

• Verified date: July 2016
• Source: Bioview, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review BoardIsrael: Ministry of Health
• Study type: Observational

Clinical Trial Summary

Early detection of lung cancer and early removal of the cancer nodules facilitates the diagnosis and treatment. However, not all nodules are malignant. Currently the standard method to diagnose lung cancer is to remove any suspicious nodules from the lung in a surgical procedure.

This study is being conducted to evaluate the performance of a laboratory test to detect changes in lung cells that might be an early indicator of lung cancer. The test uses mucus (sputum) which is collected in a non-invasive method. This study will compare the results of the lung biopsy with the laboratory test to determine if the test can detect cancer or the lack of cancer.

The laboratory test will not be shared with the treating physician or the patient as the current standard for lung cancer diagnosis is a biopsy. Approximately 330 patients will be enrolled in the study. There is one visit involved and includes the collection of a sputum specimen by coughing into a cup. The medical records of patients who are negative for cancer by biopsy will be reviewed for 2 years to detect any changes in diagnosis.

Description:

This study is being conducted to evaluate the performance of a laboratory test to detect changes in lung cells that might be an early indicator of lung cancer. The test uses mucus (sputum) which is collected in a non-invasive method. This study will compare the results of the lung biopsy with the laboratory test to determine if the test can detect cancer or the lack of cancer.

The laboratory test will not be shared with the treating physician or the patient as the current standard for lung cancer diagnosis is a biopsy. Approximately 330 patients will be enrolled in the study. There is one visit involved and includes the collection of a sputum specimen by coughing into a cup. The medical records of patients who are negative for cancer by biopsy will be reviewed for 2 years to detect any changes in diagnosis.

The results of the test will not be provided to the subject, the investigator and will not be used to diagnose or treat the subject.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 173
• Est. completion date: April 2016
• Est. primary completion date: April 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects with 0.8-3 cm solitary pulmonary nodules with high probability for malignancy

• Candidate is scheduled to undergo lung biopsy procedure to determine clinical diagnosis, such as Bronchoscope biopsy, Electromagnetic Navigation Bronchoscopy, fiber optic Bronchoscopy, Needle biopsy, CT guided, Percutaneous Transthoracic Needle biopsy, Transthoracic Needle Biopsy, Open biopsy for Diagnostic Resection or Video-Assisted Thorascopic Surgery.

• Candidate who is capable of undergoing sputum induction.

• Ability to understand the investigational nature of the study and sign the informed consent.

Exclusion Criteria:

• Subjects who pose a high clinical risk for diagnostic bronchoscopy or transthoracic biopsy for definitive diagnosis.

• Subjects already diagnosed with lung cancer, or previously treated for lung cancer.

• Subjects who experienced pneumonia within last 12 weeks.

• Subjects who experienced an acute respiratory infection within the last 2 weeks

• Cases without sufficient documentation of diagnosis or follow-up will not be included.

• Treatment for, or evidence of any cancer other than nonmelanoma skin cancer or carcinoma in situ within the last 3 years.

• Subject who lack the capacity to consent.

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Lung Cancer
• Lung Neoplasms

Locations

Country	Name	City	State
Israel	Kaplan Medical Center	Rehovot
Israel	Sheba Medical Center Thoracic Cancer Research and Detection Center	Tel Hashomer
Israel	Tel-Aviv Sourasky Medical Center	Tel-Aviv
United States	St. Luke's Hospital	Bethlehem	Pennsylvania
United States	Frederick Memorial Hospital, Regional Cancer Center	Frederick	Maryland
United States	VA Greater Los Angeles Health System	Los Angeles	California

Sponsors (1)

Lead Sponsor	Collaborator
Bioview, Inc.

Countries where clinical trial is conducted

United States,  Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determination of concordance of the Target-Fish LCD Test and diagnosis by biopsy	Subjects suspected of having of having lung cancer and who are to undergo biopsy will undergo sputum sampling. The sputum will be assayed using the BioView test kit. Biopsy results will be compared with the assay results, each being a dichotomous response (positive or negative for cancer by biopsy, positive or negative assay result using client-supplied cut-off). Since the assay may detect cancer before a biopsy is positive or because the sputum sampling may be more representative of the condition of the lung than just the biopsied nodule, it will be necessary to follow thte negative biopsy subjects for up to two years to either rule in or rule out lung cancer.	2 weeks following sputum collection	No